指南与共识前列腺癌

多参数磁共振成像在活检中排除前列腺癌的阴性预测值是什么?欧洲泌尿外科学会前列腺癌指南小组的系统评价与荟萃分析

What Is the Negative Predictive Value of Multiparametric Magnetic Resonance Imaging in Excluding Prostate Cancer at Biopsy? A Systematic Review and Meta-analysis from the European Association of Urology Prostate Cancer Guidelines Panel.
指南 / 共识 · Eur Urol · 2017-03-21

该系统评价与荟萃分析纳入48项研究共9613例患者,评估多参数磁共振成像(mpMRI)排除前列腺癌的阴性预测值(NPV)。患者层面总癌症中位NPV为82.4%,临床显著前列腺癌(csPCa)中位NPV为88.1%;NPV随癌症患病率升高而显著下降。结论认为mpMRI的NPV因研究设计、癌症患病率及阳性mpMRI和csPCa定义而异,风险分层应作为考虑活检前mpMRI前的初始步骤。

要点

  • 总癌症中位NPV为82.4%,csPCa中位NPV为88.1%。
  • 总癌症患病率从30%升至60%时,cut-off 3/5的合并NPV从88%降至67%。
  • mpMRI尚不够准确以替代前列腺活检,其准确性受前列腺癌风险影响。

核心结论

  • mpMRI的NPV因研究设计、癌症患病率以及阳性mpMRI和csPCa的定义而差异很大。
  • 由于各系列癌症患病率高度可变,风险分层应作为考虑活检前mpMRI之前的初始步骤,并确定哪些患者在mpMRI阴性时可省略活检。

研究设计与样本

  • 系统评价与荟萃分析,由欧洲泌尿外科学会前列腺癌指南小组完成。
  • 检索Embase、Medline和Cochrane数据库至2016年2月。
  • 共48项研究(9613例患者)符合纳入标准;8项研究符合荟萃分析纳入标准,其中7项报告总前列腺癌结果。

主要发现

  • 患者层面总癌症中位患病率为50.4%(IQR 36.4-57.7%),csPCa中位患病率为32.9%(IQR 28.1-37.2%)。
  • 总癌症中位mpMRI NPV为82.4%(IQR 69.0-92.4%),csPCa中位NPV为88.1%(IQR 85.7-92.3%)。
  • 总癌症患病率增加时NPV显著下降(r=-0.64,p<0.0001),csPCa患病率增加时NPV亦显著下降(r=-0.75,p=0.032)。
  • 总前列腺癌患病率从30%升至60%时,cut-off 3/5的合并NPV从88%(95%CI 77-99%)降至67%(95%CI 56-79%)。
  • 仅1项荟萃分析纳入研究报告Gleason≥7癌症结果,活检阳性率为29.3%,cut-off≥3/5的相应NPV为87.9%。

临床怎么用

  • 风险分层应作为考虑活检前mpMRI之前的初始步骤,并确定哪些患者在mpMRI阴性时可省略活检。
  • mpMRI是有前景的工具,但尚不够准确以在此类患者中替代前列腺活检。
  • 若有更准确的方法确定前列腺癌风险,mpMRI性能可增强;当此类工具可用时,应有可能对低风险前列腺癌患者使用MRI扫描以避免活检。

局限性

  • mpMRI的NPV因研究设计、癌症患病率以及阳性mpMRI和csPCa定义而异。
  • 各系列癌症患病率高度可变。
  • 仅1项荟萃分析纳入研究报告Gleason≥7癌症结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: It remains unclear whether patients with a suspicion of prostate cancer (PCa) and negative multiparametric magnetic resonance imaging (mpMRI) can safely obviate prostate biopsy. OBJECTIVE: To systematically review the literature assessing the negative predictive value (NPV) of mpMRI in patients with a suspicion of PCa. EVIDENCE ACQUISITION: The Embase, Medline, and Cochrane databases were searched up to February 2016. Studies reporting prebiopsy mpMRI results using transrectal or transperineal biopsy as a reference standard were included. We further selected for meta-analysis studies with at least 10-core biopsies as the reference standard, mpMRI comprising at least T2-weighted and diffusion-weighted imaging, positive mpMRI defined as a Prostate Imaging Reporting Data System/Likert score of ≥3/5 or ≥4/5, and results reported at patient level for the detection of overall PCa or clinically significant PCa (csPCa) defined as Gleason ≥7 cancer. EVIDENCE SYNTHESIS: A total of 48 studies (9613 patients) were eligible for inclusion. At patient level, the median prevalence was 50.4% (interquartile range [IQR], 36.4-57.7%) for overall cancer and 32.9% (IQR, 28.1-37.2%) for csPCa. The median mpMRI NPV was 82.4% (IQR, 69.0-92.4%) for overall cancer and 88.1% (IQR, 85.7-92.3) for csPCa. NPV significantly decreased when cancer prevalence increased, for overall cancer (r=-0.64, p<0.0001) and csPCa (r=-0.75, p=0.032). Eight studies fulfilled the inclusion criteria for meta-analysis. Seven reported results for overall PCa. When the overall PCa prevalence increased from 30% to 60%, the combined NPV estimates decreased from 88% (95% confidence interval [95% CI], 77-99%) to 67% (95% CI, 56-79%) for a cut-off score of 3/5. Only one study selected for meta-analysis reported results for Gleason ≥7 cancers, with a positive biopsy rate of 29.3%. The corresponding NPV for a cut-off score of ≥3/5 was 87.9%. CONCLUSIONS: The NPV of mpMRI varied greatly depending on study design, cancer prevalence, and definitions of positive mpMRI and csPCa. As cancer prevalence was highly variable among series, risk stratification of patients should be the initial step before considering prebiopsy mpMRI and defining those in whom biopsy may be omitted when the mpMRI is negative. PATIENT SUMMARY: This systematic review examined if multiparametric magnetic resonance imaging (MRI) scan can be used to reliably predict the absence of prostate cancer in patients suspected of having prostate cancer, thereby avoiding a prostate biopsy. The results suggest that whilst it is a promising tool, it is not accurate enough to replace prostate biopsy in such patients, mainly because its accuracy is variable and influenced by the prostate cancer risk. However, its performance can be enhanced if there were more accurate ways of determining the risk of having prostate cancer. When such tools are available, it should be possible to use an MRI scan to avoid biopsy in patients at a low risk of prostate cancer.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Moldovan PC, Van den Broeck T, Sylvester R, et al. What Is the Negative Predictive Value of Multiparametric Magnetic Resonance Imaging in Excluding Prostate Cancer at Biopsy? A Systematic Review and Meta-analysis from the European Association of Urology Prostate Cancer Guidelines Panel. Eur Urol. 2017. PMID: 28336078. doi:10.1016/j.eururo.2017.02.026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。